SynthesisFrontiers in pharmacology2025

Subcutaneous versus intravenous trastuzumab for HER2-positive breast cancer: a global systematic review and meta-analysis with a cost-minimization analysis from the Chinese healthcare system perspective.

Zheng Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.